Shenwan Hongyuan Holdings Ltd. (WAY)

Overview

Ziccum AB (publ) is a pioneering biotechnology company based in Lund, Sweden, that was established in 2017. The company focuses on the development of dry powder preparations of biological pharmaceuticals, leveraging innovative technology to address the challenges associated with liquid biopharmaceutical forms. By transforming these sensitive biological materials into stable, particle-engineered powder products, Ziccum AB aims to revolutionize the storage, transportation, and delivery of vaccines and protein therapeutics. This forward-thinking approach not only aims to enhance the accessibility of these vital medications but also seeks to extend their reach to under-served regions worldwide.

Products and Services

• LaminarPace

Ziccum AB's flagship technology, LaminarPace, represents a substantial advancement in the field of biopharmaceuticals. This cutting-edge spray drying technology is designed to dry liquid biopharmaceuticals, such as vaccines or protein therapeutics, into a particle-engineered powder product. The transformation process ensures that the final powdered form maintains the integrity and efficacy of the original biological materials, thereby overcoming some of the biggest challenges in the biopharmaceutical industry. The potential applications of LaminarPace extend across various domains, including vaccine dissemination in climates that challenge cold-chain logistics and in scenarios where long-term storage stability is paramount. By facilitating the conversion of critical medications into more stable and easily distributable forms, LaminarPace stands as a key innovation in global healthcare advancements.